Personalis (NASDAQ:PSNL) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Valuation and Earnings

This table compares Personalis and Enzo Biochem’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Personalis N/A N/A N/A N/A N/A
Enzo Biochem $104.71 million 1.45 -$10.32 million N/A N/A

Personalis has higher earnings, but lower revenue than Enzo Biochem.

Insider and Institutional Ownership

16.8% of Personalis shares are held by institutional investors. Comparatively, 63.1% of Enzo Biochem shares are held by institutional investors. 9.4% of Enzo Biochem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Personalis and Enzo Biochem, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Personalis 0 1 4 0 2.80
Enzo Biochem 0 0 0 0 N/A

Personalis presently has a consensus target price of $28.25, suggesting a potential upside of 44.06%. Given Personalis’ higher probable upside, equities research analysts plainly believe Personalis is more favorable than Enzo Biochem.

Profitability

This table compares Personalis and Enzo Biochem’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Personalis N/A N/A N/A
Enzo Biochem 2.49% -34.02% -27.09%

Personalis Company Profile

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.

Enzo Biochem Company Profile

Enzo Biochem, Inc., an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing ‘STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.